Spark Therapeutics Now Targets 2017 For US Approval Of First Retinal Gene Therapy

Two manufacturing control assays have taken longer to develop than previously thought, putting back completion of a BLA submission to early 2017 for US company Spark Therapeutics, while further progress has been made in the company’s early-stage hemophilia gene therapy program.